Summary & Overview
HCPCS C9493: Injection, Edaravone, 1 mg
HCPCS Level II code C9493 designates a 1 mg unit of edaravone administered by injection. Edaravone is used in specialized clinical settings as a neuroprotective agent, and the code enables itemized billing for each 1 mg dose delivered. Nationally, precise coding for high-cost parenteral therapies matters for payment accuracy, utilization tracking, and formulary management.
Key payers relevant to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9493 represents clinically and operationally, payer coverage context, and common billing considerations. The publication provides benchmarks and policy context where available, clarifies typical sites of service for administration, and outlines what data elements are and are not present in the input. The content is intended to inform coding staff, revenue cycle teams, and policy analysts about the role of C9493 in claims processing and clinical billing workflows.
Billing Code Overview
HCPCS Level II code C9493 represents injection, edaravone, 1 mg, a parenteral pharmaceutical administration. The service type is an intravenous or intramuscular drug administration for a single 1 mg unit of edaravone. The typical site of service is outpatient infusion centers, hospital outpatient departments, or physician office-based infusion suites where parenteral neuroprotective or disease-modifying therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a confirmed diagnosis of amyotrophic lateral sclerosis (ALS) who is receiving intravenous edaravone for disease modification. The patient attends an outpatient infusion center or hospital outpatient department for scheduled therapy. The clinical workflow includes pre-infusion nursing assessment (vital signs, allergy review, pregnancy status if applicable), verification of physician order for C9493 dosed per milligram, preparation of the medication by pharmacy to the ordered concentration, venous access placement (peripheral IV or established central line), administration of edaravone over the authorized infusion time, monitoring for infusion reactions or adverse events during and for a period after infusion, documentation of lot number and amount administered, and discharge instructions. Typical site of service is an outpatient infusion center or hospital outpatient department. Common scenario modifiers include coding for multiple procedures or unusual circumstances using modifier 51 when applicable to represent multiple concurrent services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
51 | Multiple procedures — multiple surgeries, or several procedures billed on the same day | Use when multiple distinct services are reported the same day in addition to the drug administration and payer allows modifier use for bundling determination |